News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Gilead Sciences, Inc. Profit Rises a Higher-than-Expected 21 Percent
April 21, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Gilead Sciences Inc (GILD.O) said on Tuesday first-quarter profit rose 21 percent, topping analysts' expectations, on increased sales of its drugs to treat the virus that causes AIDS.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Leadership
Vaxart seeks shareholder support as battle over stock split brews
May 21, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Deals
Lilly and Engage Bio tie the knot with $202M acquisition
May 20, 2026
·
2 min read
·
Gabrielle Masson
Manufacturing
FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions
May 20, 2026
·
2 min read
·
Nick Paul Taylor
